Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8789735 | 0.90 | ABCG2 (0.50) | ABCG2TP53MEN1KMT2APBRM1 | |
| SCHEMBL8790879 | 0.84 | ABCG2 (0.50) | ABCG2TP53MEN1KMT2APBRM1 | |
| SCHEMBL8790679 | 0.84 | ABCG2 (0.59) | ABCG2TP53MEN1KMT2AMAPT | |
| SCHEMBL8788654 | 0.82 | TP53 (0.48) | ABCG2TP53MAOBMEN1KMT2A | |
| SCHEMBL8790584 | 0.82 | ABCG2 (0.52) | ABCG2TP53MEN1KMT2APBRM1 | |
| SCHEMBL8789743 | 0.81 | ABCG2 (0.58) | ABCG2TP53MEN1KMT2APBRM1 | |
| SCHEMBL8789120 | 0.80 | ABCG2 (0.63) | ABCG2TP53MEN1KMT2AMAPT | |
| SCHEMBL8791527 | 0.80 | ABCG2 (0.51) | ABCG2TP53MEN1KMT2APBRM1 | |
| SCHEMBL8788702 | 0.79 | ABCG2 (0.59) | ABCG2TP53MEN1KMT2AKDR | |
| SCHEMBL8836061 | 0.78 | ABCG2 (0.63) | ABCG2TP53MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0569380-B1 | ACRIDINE DERIVATIVES | GLAXO LAB SA (FR) | 1997-05-28 | — | — | EP | disclosed |
| US-5604237-A | IMPROVE OR INCREASE EFFICACY OF ANTITUMOR AGENT, INCREASE OR RESTORE SENSITIVITY OF TUMOR TO ANTITUMOR AGENT, REVERSE OR REDUCE RESISTANCE OF TUMOR TO ANTITUMOR AGENT | LABORATOIRES GLAXO SA (FR) | 1997-02-18 | — | — | US | disclosed |
| EP-0494623-A1 | Acridine derivatives | LABORATOIRES GLAXO SA (FR) | 1992-07-15 | — | — | EP | disclosed |